Your browser doesn't support javascript.
loading
Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.
Jiao, Xiao-Dong; Zhang, Xiao-Chun; Qin, Bao-Dong; Liu, Dong; Liu, Liang; Ni, Jian-Jiao; Ning, Zhou-Yu; Chen, Ling-Xiang; Zhu, Liang-Jun; Qin, Song-Bing; Ying, Shen-Peng; Chen, Xue-Qin; Li, Ai-Jun; Hou, Ting; Han-Zhang, Han; Ye, Junyi; Zheng, Jingjing; Chuai, Shannon; Zang, Yuan-Sheng.
Affiliation
  • Jiao XD; Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
  • Zhang XC; Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
  • Qin BD; Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
  • Liu D; Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
  • Liu L; Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ni JJ; Departments of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Ning ZY; Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Chen LX; Department of Internal Medicine, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Zhu LJ; Department of Internal Medicine, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Qin SB; Department of Tumor Radiotherapy, The First Affiliated Hospital of Suzhou University, Suzhou, China.
  • Ying SP; Department of Radiotherapy, Taizhou Central Hospital, Taizhou University Hospital, Taizhou, China.
  • Chen XQ; Department of Thoracic Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Li AJ; Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
  • Hou T; Burning Rock Biotech, Guangzhou, China.
  • Han-Zhang H; Burning Rock Biotech, Guangzhou, China.
  • Ye J; Burning Rock Biotech, Guangzhou, China.
  • Zheng J; Burning Rock Biotech, Guangzhou, China.
  • Chuai S; Burning Rock Biotech, Guangzhou, China.
  • Zang YS; Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Ann Transl Med ; 8(14): 860, 2020 Jul.
Article de En | MEDLINE | ID: mdl-32793704
ABSTRACT

BACKGROUND:

Tumor mutation burden (TMB) has an important association with immunotherapy responses. TMB in the Chinese population has not been well established. Finding differences between the Chinese and Caucasian populations and elucidating the underlying biological mechanisms of high TMB might help develop more precise and effective means for TMB and immunotherapy response prediction.

METHODS:

Chinese cancer patients fresh tissue (n=2,177), formalin-fixed, paraffin-embed (FFPE) specimens (n=3,294), and pleural fluid (n=189) were profiled using a 295- or 520-gene next-generation sequencing (NGS) panel. The association of the TMB status with a series of molecular features and biological pathways was determined using bootstrapping.

RESULTS:

TMB, measured by 295- or 520-cancer-related gene panels, was correlated with whole-exome sequencing (WES) TMB based on the in silico simulation in The Cancer Genome Atlas cohort. The median TMB of our data was slightly higher than that from the Foundation Medicine Inc. (FMI) dataset. TMB was also slightly different within the same cancer type between the Chinese and Caucasian population. We discovered that the underlying pathways of TMB status varied greatly and sometimes had an opposite association with TMB across different cancer types. Moreover, we developed a 23-gene and a 16-gene signature to predict TMB prediction for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), respectively, indicating a histology-specific mechanism for driving high-TMB in lung cancer.

CONCLUSIONS:

TMB varies among different ethnic populations. Our findings extend the knowledge of the underlying biological mechanisms for high TMB and might be helpful for developing more precise and accessible TMB assessment panels and algorithms in more cancer types.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Ann Transl Med Année: 2020 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Ann Transl Med Année: 2020 Type de document: Article Pays d'affiliation: Chine